Who Supplies Sunitinib to India from GERMANY

To import finished pharmaceutical formulations containing Sunitinib into India, the foreign manufacturer must obtain a Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application process involves submitting Form 40/41 to CDSCO, along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The timeline for obtaining these approvals can vary but typically ranges from 6 to 12 months. Sunitinib formulations under HS Code 30049099 are subject to these regulatory requirements to ensure quality, safety, and efficacy.

Imported Sunitinib formulations must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to demonstrate product stability in India's climate. Port inspections by customs drug inspectors are conducted to verify compliance with these standards. Failure to meet quality standards can result in rejection of the batch and potential penalties.

Between 2024 and 2026, CDSCO has implemented stricter regulations for importing pharmaceutical products, including mandatory import registration and licensing. The Production-Linked Incentive (PLI) scheme has been introduced to encourage domestic manufacturing, potentially impacting the volume of finished formulation imports. Bilateral agreements between India and Germany have facilitated smoother trade relations, but compliance with updated regulatory requirements remains essential.

India imports finished Sunitinib formulations primarily due to the unavailability of certain patented or specialized dosage forms domestically. The market size for Sunitinib in India is substantial, with a growing number of patients requiring treatment for various cancers. Domestic manufacturers may lack the capacity or technology to produce specific Sunitinib formulations, leading to reliance on imports to meet patient needs.

The Basic Customs Duty (BCD) for Sunitinib formulations under HS Code 30049099 is 10%. A Social Welfare Surcharge (SWS) of 10% on BCD is applicable. Integrated Goods and Services Tax (IGST) is levied as per prevailing rates, which can vary. There are no specific exemptions or preferential duty rates for imports from Germany. The total landed duty percentage depends on the CIF value and applicable IGST rates.

India sources Sunitinib formulations from Germany due to the country's strong pharmaceutical manufacturing capabilities, adherence to international quality standards, and the availability of specialized dosage forms not produced domestically. Germany's share in India's Sunitinib import market is significant, with other suppliers like China, the US, and domestic manufacturers also contributing to the market. Germany's competitive advantage lies in its established reputation for quality and innovation in pharmaceutical products.

India imports Sunitinib formulations from Germany due to the availability of patented formulations and specialized dosage forms not produced domestically. Germany's advanced pharmaceutical manufacturing capabilities and adherence to international quality standards make it a preferred source. Specific formulations, such as certain extended-release tablets, are not manufactured in India, necessitating imports to meet patient needs.

Compared to other sources like China, the EU, and the US, Germany offers a competitive advantage in terms of product quality, regulatory compliance, and reliability. While China may offer lower prices, concerns about quality and regulatory standards make Germany a more reliable choice. The US provides high-quality products but at higher costs, making Germany a balanced option.

Potential risks include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have been minimal, but it's prudent to monitor the supply chain regularly. Diversifying suppliers and maintaining adequate inventory levels can mitigate some of these risks.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain buffer stock to manage supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letter of Credit (LC) to manage financial risk.
4. 4Supplier Qualification: Conduct thorough due diligence to ensure compliance with quality and regulatory standards.
5. 5Regulatory Compliance: Stay updated with changes in import regulations and ensure all necessary licenses and certifications are in place.

1. 1DGFT Importer-Exporter Code (IEC): Obtain an IEC for customs clearance.
2. 2CDSCO Registration Certificate: Apply using Form 40/41, including necessary documents.
3. 3Drug Import License: Obtain as per the Drugs and Cosmetics Act.
4. 4No Objection Certificate (NOC): If required, obtain from relevant authorities.
5. 5Customs Broker: Engage a licensed customs house agent for clearance.
6. 6Advance Ruling: Seek clarification on classification and duty rates if needed.

1. 1Certificate of Analysis (CoA): Confirming product quality.
2. 2Certificate of Pharmaceutical Product (CoPP): As per WHO guidelines.
3. 3Good Manufacturing Practice (GMP) Certificate: Ensuring manufacturing standards.
4. 4Drug Master File (DMF): Providing detailed product information.
5. 5Stability Data: For ICH Zone IVa/IVb conditions.